KPTI News and Press, Karyopharm Therapeutics Inc. From 10/31/22

Karyopharm and Menarini Group Announce Orphan Medicinal Product Designation from the European Commission for Selinexor for the Treatment of Myelofibrosis PR Newswire NEWTON, Mass. and FLORENCE, Italy , Oct. 31, 2022 /PRNewswire/ -- Karyopharm T...

Karyopharm to Report Third Quarter 2022 Financial Results on November 3, 2022 PR Newswire -- Conference Call Scheduled for Thursday, November 3, 2022 , at 4:30 p.m. ET -- NEWTON, Mass. , Oct. 20, 2022 /PRNewswire/ -- Karyopharm Therapeuti...

Summary Karyopharm's growth strategy has generated significant increases in total revenues, net product revenue growth, licensing revenue, and milestone revenue. Despite the progress, the market continues to punish KPTI. The company is focusing on XPOVIO to maximize growth in mult...

Karyopharm to Participate at Upcoming Investor Conferences PR Newswire NEWTON, Mass. , Sept. 7, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced ...

Penny Stocks To Buy: What To Look For This article will discuss a handful of penny stocks to buy according to those looking for short squeeze stocks. If you’ve seen our other articles about cheap stocks with high short interest, you know that there are a lot of risks that go ...

The second quarter of biotech Karyopharm Therapeutics (NASDAQ: KPTI) was a good one, at least as far as its headline figures were concerned. On the back of revenue and earnings beats, investors bid up the company's share price on the day...but only marginally, as the stock notched a...

Image source: The Motley Fool. Karyopharm Therapeutics (NASDAQ: KPTI) Q2 2022 Earnings Call Aug 04, 2022 , 8:00 a.m. ET Operator Continue reading For further details see: Karyopharm Therapeutics (KPTI) Q2 2022 Earnings Call Transcript

Karyopharm Therapeutics, Inc. (KPTI) Q2 2022 Results Conference Call August 4, 2022 08:00 AM ET Company Participants Elhan Webb - SVP, IR Richard Paulson - President, CEO & Director Sohanya Cheng - EVP & Chief Commercial Officer Mike Mason - EVP, CFO ...

Karyopharm Therapeutics press release ( NASDAQ: KPTI ): Q2 GAAP EPS of -$0.62 misses by $0.01 . Revenue of $39.68M (+75.6% Y/Y) beats by $3.72M . XPOVIO (selinexor) Net Product Revenue of $29.0 Million, a 44% Increase Over Q2 2021 For further details see:...

Karyopharm Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress PR Newswire – Achieved Second Quarter 2022 Total Revenue of $39.7 Million , Up 76% Versus Second Quarter 2021; XPOVIO® (selinexor) Net Product Revenu...